BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens

Fri Feb 13, 2026 3:32 pm JST Earnings

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Earnings Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced its financial results after the market closed on February 13th (15:32). The net loss (non-consolidated) for the cumulative third quarter of the fiscal year ending March 2026 (April to December) expanded to a loss of 955 million yen (compared to a loss of 815 million yen in the same period last year).

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the net loss for the January to March period (4Q) is expected to further decrease loss of 211 million yen (compared to a loss of 336 million yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the net loss expanded to loss of 493 million yen (compared to a loss of 277 million yen in the same period last year).

Kabutan News

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	0M	-947M	-947M	-953M	-15.1	ー	Feb 9, 2024	J-GAAP
Apr - Dec, 2024	0M	-815M	-812M	-815M	-10.3	ー	Feb 14, 2025	J-GAAP
Apr - Dec, 2025	0M	-956M	-952M	-955M	-9.1	ー	Feb 13, 2026	J-GAAP
YoY	－	-17.3%	-17.2%	-17.2%	+11.9%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	1M	-618M	-610M	-613M	-7.5	0	May 9, 2025	J-GAAP
Guidance Oct - Mar, 2025	0M	-718M	-704M	-704M	-5.2	0	Nov 14, 2025	J-GAAP
YoY	－	-16.2%	-15.4%	-14.8%	+30.7%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	0M	-1,155M	-1,158M	-1,168M	-18.2	0	May 10, 2024	J-GAAP
Mar, 2025	1M	-1,160M	-1,147M	-1,151M	-14.1	0	May 9, 2025	J-GAAP
Guidance Mar, 2026	0M	-1,182M	-1,164M	-1,166M	-8.6	0	May 9, 2025	J-GAAP
YoY	－	-1.9%	-1.5%	-1.3%	+38.9%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2024	0M	-273M	-275M	-277M	-3.5	-Inf	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	1M	-345M	-335M	-336M	-4.1	-34,500.0	May 9, 2025	J-GAAP
Apr - Jun, 2025	0M	-245M	-240M	-241M	-2.6	-Inf	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	0M	-219M	-220M	-221M	-2.2	-Inf	Nov 14, 2025	J-GAAP
Oct - Dec, 2025	0M	-492M	-492M	-493M	-4.7	-Inf	Feb 13, 2026	J-GAAP
YoY	－	-80.2%	-78.9%	-78.0%	-33.7%